Bionomics Limited (NASDAQ:BNOX) Short Interest Update

Bionomics Limited (NASDAQ:BNOX) saw a large decrease in short interest in the month of October. As of October 15th, there was short interest totalling 13,800 shares, a decrease of 81.1% from the September 30th total of 73,000 shares. Based on an average daily trading volume, of 626,600 shares, the short-interest ratio is presently 0.0 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Bionomics stock. Armistice Capital LLC purchased a new position in Bionomics Limited (NASDAQ:BNOX) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 1,226,759 shares of the company’s stock, valued at approximately $941,000. Armistice Capital LLC owned approximately 15.03% of Bionomics as of its most recent SEC filing. Institutional investors and hedge funds own 15.90% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $8.00 target price on shares of Bionomics in a report on Thursday, August 1st.

Bionomics Trading Down 31.5 %

Bionomics stock traded down $0.11 during mid-day trading on Friday, hitting $0.25. The stock had a trading volume of 4,017,426 shares, compared to its average volume of 541,273. The firm’s 50 day moving average is $0.50 and its 200 day moving average is $0.71. Bionomics has a one year low of $0.23 and a one year high of $3.03.

About Bionomics

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.